反応式
[CH3:1][C:2]([O:7][CH3:8])([CH2:4][N+:5]#[C-:6])[CH3:3].O.O.C([O-])(=O)CC(CC([O-])=O)(C([O-])=O)O.[Na+].[Na+].[Na+].O.Cl.N[C@H](C(O)=O)CS.C(O)[C@H]([C@H]([C@@H]([C@@H](CO)O)O)O)O.[Tc:48]([O-])(=O)(=O)=O.[Na+]>>[CH3:1][C:2]([O:7][CH3:8])([CH2:4][N:5]=[CH-:6])[CH3:3].[CH3:1][C:2]([O:7][CH3:8])([CH2:4][N:5]=[CH-:6])[CH3:3].[CH3:1][C:2]([O:7][CH3:8])([CH2:4][N:5]=[CH-:6])[CH3:3].[CH3:1][C:2]([O:7][CH3:8])([CH2:4][N:5]=[CH-:6])[CH3:3].[CH3:1][C:2]([O:7][CH3:8])([CH2:4][N:5]=[CH-:6])[CH3:3].[CH3:1][C:2]([O:7][CH3:8])([CH2:4][N:5]=[CH-:6])[CH3:3].[Tc+6:48]参加物
実験手順
The kit includes a lyophilized mixture of a copper complex of MIBI (tetrakis(2-methoxyisobutylisonitrile)copper(I) tetrafluoroborate ([Cu(MIBI)4]BF4)) as the active ingredient, sodium citrate dihydrate as a buffer, L-cysteine hydrochloride monohydrate as a stabilization aid, mannitol as a lyophilization aid, and stannous chloride dihydrate as a reducing agent. Prior to use, the lyophilized mixture is reconstituted with sodium pertechnetate (99mTc) and boiled to form technetium (99mTc) Sestamibi. The U.S. Pharmacopoeia (29th Ed.) requires that a mean of not less than 90% (corrected area percentage) of the total radioactivity is represented by 99mTc-Sestamibi, and a mean of not more than 5% (corrected area percentage) of the total radioactivity is present as 99mTc pentamibi dimethylvinyl isonitrile.
出典と根拠
- ORDレコード
- ord-c29979385a85440daab97c55eaa6bf78
- 出典データセット
- uspto-grants-2014_04
- 特許番号
- US08703987B2
関連ノート
読み込み中…